Category Archives: Alternative Medicine

A file photo of Lagos state Governor, Babajide Sanwo-Olu.

The Lagos State Government, through the Traditional Medicine Board (LSTMB), says it will begin its clamps down on unregistered practitioners of Complementary and Alternative Medicine (CAM) in every part of the country.

This was disclosed in a statement by the Public Affairs Officer of the board, Segun Ogunleye on Tuesday.

According to the statement, the government is set to enforce the directives of the National Council on Health (NCH), which mandates all practitioners of Complementary and Alternative Medicine to register their operations or face the full wrath of the law, as prescribed by the National Council on Health.

Speaking recently in Lagos about the NCH directives, which he said were part of the resolutions reached at the 62nd meeting of the Traditional Medicine Practitioners held in 2019 in Asaba, Delta State, Registrar of the Lagos State Traditional Medicine Board, Mr. Olorunkemi Kadiku, said the board is giving unregistered practitioners in the state till the end of March to complete their registration.

Read Also: Abba Kyari: IGP Orders Closure Of All Intelligence Response Teams, Special Tactical Squad Satellite Units

According to him, all Complementary and Alternative Medicine Practitioners including product manufacturers, importers, wholesalers, and retailers are required to regularise their practice, as well as register their premises with the Traditional Medicine Board, or risk their premises being sealed.

Any practitioner that fails to comply with this directive to register with LSTMB, would be treated as defaulter and such premises sealed off, including confiscation of products, in line with the councils decisions, he said.

Speaking further on the issue, Kadiku, who is also a member of the states Primary Health Care Board, disclosed that the Traditional Medicine Board has equally complied with other directives of the National Council, mandating all Traditional Medicine Boards to establish notable professional units or sections, in their offices, to be in charge of coordination, regulation and control of CAM practice and products.

The units, according to the Board helmsman, include: Traditional Medicine Practice, Complementary and Alternative Medicine Practice, Traditional, Complementary and Alternative Medicine Practice, Research Development, Herbal Complementary Medical Products and Commercialisation.

Explaining further, the Registrar said the board has equally gone ahead to implement the councils resolution by registering and licensing Milyash Alternative Specialist Clinic at Adetokunbo Ademola Street, Victoria Island, as the first Complementary and Alternative Medicine Clinic, in the state, adding that the Board is also in the process of registering other Facilities that have applied to it, for registration.

According to Kadiku, the LSTMB was established by the state government in 1980, to oversee the development, promotion, monitoring, regulation and integration of traditional medicine practices into the healthcare of the state.

See more here:

Lagos To Clamp Down On Unregistered Alternative Medicine Practitioners - Channels Television

FLINT, Mich., Feb. 16, 2022 /PRNewswire/ --Forum Health, LLC, nationwide network of integrative and functional medicine providers, has acquired Calmglow Functional Medicine located in Modesto, CA.

Calmglow is a functional medicine practice founded and led by Nurse Practitioner and Physician Assistant, Dianne Hinton, who brings over 30 years of primary care, surgical, internal medicine, and functional medicine experience.

"We're thrilled to welcome Dianne Hinton and Calmglow to Forum Health," said Adam Puttkammer, president of Forum Health. "Her expertise in alternative treatments and the latest methods to support vitamin deficiencies, hormone imbalances, anti-aging, and chronic illnesshas positioned Dianne and her team as leaders in functional medicine in Modesto."

Calmglow is a patient-centered practice that treats individuals based on their unique needs, data, lifestyle, and history with a focus on addressing the underlying causes of disease. The clinic specializes in digestive and immune health, weight loss, pain management, hormone imbalance, detoxification, emotional wellness and mental health, the endocrine and lymphatic systems, cardiovascular health, and the musculoskeletal system.

"I'm enthusiastic to join Forum Health because their philosophy aligns with my belief that functional medicine celebrates the human body in a holistic fashion, rather than separate parts," said Dianne Hinton. "Through this relationship, we can help more people take an active role in their health to live a vibrant life."

"Dianne Hinton and her team exemplify everything we look for in a Forum Health clinic," said Phil Hagerman, CEO of Forum Health. "Their commitment to providing healthy solutions as an alternative to traditional medicine to the Modesto community is key in Forum Health's mission to set a new standard of healthcare.

For more on Forum Health and how to become a practitioner, visit http://www.forumhealth.com.

About Forum Health, LLCForum Health, LLC is a nationwide provider of personalized healthcare. Steeped in the powerful principles of functional and integrative medicine, Forum Health providers take a root-cause approach to care. They listen and dig deep exploring lifestyle, environment, and genetics to help each patient achieve their ultimate health goals. Members have access to advanced medical treatments and technology, with care plans informed by data analytics and collaborative relationships. To learn more, visit forumhealth.com.

SOURCE Forum Health, LLC

See the article here:

Forum Health Welcomes Calmglow Functional Medicine as its Second Location in California - PRNewswire

Mel B of the Spice Girls, aka Scary Spice, aka Melanie Janine Brown, has been named as the UK "face" of the West Indies island Nevis. "I am soooo proud and honoured that I have been made ambassador to Nevismy dad's homeland yipppeeeeee!!!" she captioned a photo of her wearing a white bathing suit in crystal clear blue waters. "It's the most incredible island in the world and I want to help make sure EVERYONE sees just how amazingly beautiful It truly is. From the people, the food, the music, the setting and the feeling you have when your there Nevis is such a special place #myroots #myfamily #NevisNice #Nevis #CaribbeanTravel #nevisnaturally," she captioned it. How does the new ambassador stay so fit? Read on to see 6 ways Mel B stays in shape and the photos that prove they workand to get beach-ready yourself, don't miss these essential 30 Best-Ever Celebrity Bathing Suit Photos!

"I keep it simple. For breakfast I'll whip up a quick smoothie with coconut water, greek yoghurt, and whatever fruit I have around me, like banana and blue berries and granola," she told Body + Soul. "I'll have some dark rye avocado toast for lunch with a leafy green salad and grilled chicken for dinner with some stir-fry veggies. I snack on a mix of Brazil nuts, almonds and fruit throughout the day and try to keep my chocolate intake to two squares after dinner every other day."df44d9eab23ea271ddde7545ae2c09ec

"Do what you enjoy. There's no point forcing yourself to do some workout you hate. If you're going to commit to looking after your body, love what you're doing so it becomes easy for you. And change things up if it gets boring!" she told Body + Soul. "I never do the same everyday. Also really important is having great music to listen to; my favorite UK garage or 90s R&B. I love working out with a friend too so you kill two birds with one stone."

"30 minutes is a perfect amount of time to focus on your core. I'll just go hard on my abs for half an hour, alternating between side planks, sit-ups, leg lifts and some work with the med ball," she told Body + Soul. For abs that show, also give up sugar and increase fiber.

Before performing with the Spice Girls, Mel B would do some reiki healing, a form of energy healing in which universal energy is passed through the palms of the healer to the subject. She was ahead of her time. "Complementary and alternative medicine (CAM) is the popular name for health care practices that traditionally have not been part of conventional medicine. In many cases, as evidence of efficacy and safety grows, these therapies are being combined with conventional medicine," says the Mayo Clinic. "Thus, the term alternative has been dropped and replaced with newer terms, such as complementary and integrative medicine, integrative medicine and health, or just integrative medicine."

Mel recorded some bedtime stories for the meditation app Yours. "Not only are the tender tales perfectly designed to help you relax after a hard day, Mel's husky voice is so incredibly soothing that people will lose themselves in dreamland in no time at all," said editorial director Christian Guiltenane. Just don't check your phone too much before bed. More and more we're learning that our artificially illuminated world is simply devastating our sleep. When you check your email in bed before going to sleepor you dive into that new Grisham novel on your iPadand the shorter-wavelength (or "blue") light hits the photosensitive cells in your eye, it effectively slows the release of "sleep-promoting" neurons and "activates arousal-promoting" neurons. It suppresses the release of melatonin, the brain's chemical for making you sleepy.

Mel B was one of the many millions of people who had COVID symptoms last longer than just a few weeks. This can be called Long COVID. "In my head I'm here," she once captioned a photo of the Maldives, "ahhhh what a beautiful place, sunshine crystal clear sea being totally spoilt rotten in my private villa named after mebut in reality right now I'm curled up in bed getting over the final long haul of COVID #itsbeen5weeksnow #takemeback to #paradise #covidisnojoke #mydogs #thebestsnuggler thank god for #netflix." If you feel you have Long COVID, talk to a doctor about your symptoms or find a Post-COVID center near you.

How does Mel B look so great at age 46? "I've done everything. I did vegan for a couple of weeks, a gluten-free food delivery that me and my husband tried for a few of days, juice cleanses," the onetime America's Got Talent host told People. "Overall I like to make sure I eat a good amount of protein and vegetables. I don't have a secret," she says. "Everything in moderation."

Read more:

Scary Spice Mel B in Bathing Suit is So Proud in West Indies Celebwell - Celebwell

Palm Coast, FL, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Gold River Productions, Inc. (OTC Pink: GRPS) announces the appointment of Defense Aerospace engineer and executive Dr. Gabe Vlad as Chief Technical Officer. Dr. Vlad brings outstanding skills and experience to Gold River including vast dealings with government and commercial contracts for advanced research/engineering, business/manufacturing/production and intellectual property levels and will be actively involved in algorithm development, science and engineering research and monetization of Gold River. Additionally, Dr. Vlad's current and past government contract experience adds a new and rare dimension to our government initiatives.

Dr. Vlad was the missing link to our platform at Gold River, explains Chairman of the Board, Richard Goulding, M.D. I am so excited to be working with him. He is developing an algorithm for our products, creating an alternative cookbook for medicine. Furthermore, hes a source for value-added resources for Gold River. His Internal Revenue Code Section 501(c)(3) corporation, Stem of Hope, an associated non-profit, which like Epidemologic Solutions Corporation (www.epidemiologicsolutions.com), which has funded much of Gold Rivers initiatives, focuses on alternative treatments to support veterans and those in need.

I witnessed firsthand Drs. Bond and Gouldings products performance, says Dr. Vlad, and look forward to developing a simple alternative platform for complex and dynamic conditions that I believe has the potential to improve medicine as we know it. I cannot wait until the public experiences this platform firsthand, he added. Imagine a doctor visit, where the physician focuses on preventing illness, while avoiding side effects, all while addressing the core reasons for the individuals distress. Then imagine that the effort is coordinated in an algorithm on your smartphone that is geared towards wellness in real time. This is true longevity, where the individual feels better and has the potential for longer, more satisfying, healthier years. My contacts in the government will find this very enticing.

Dr. Vlad explained further, I know what shareholders want as I have been actively involved with a number of public and private companies. I know the value of what Gold River has created, how to enhance that value, and how to maximize Gold Rivers accompanying benefits. My patent experience will be utilized well in this endeavor. I truly believe that our team can deliver a unique health-focused platform that could improve countless lives, including military personnel and veterans, and bring great value to our company and its shareholders.

About Gold River Productions, Inc.Dedicated to changing peoples lives, Gold River is a groundbreaking company aiming at improving quality of life and longevity.Our diverse products and interests involve the use of herbal extracts from the most powerful plants, utilizing the most effective part of the plant and combining ingredients for maximum efficacy. With a unique staff of physicians, herbal medicine physicians and formulators, and business experts, we are poised to address different medical concerns without harmful pharmaceuticals.Our gummy products including Calming Mango, Relief Raspberry, and Sleepy Watermelon are now available to the public. Our future products have just finished R&D, and exceptional approval by customer sampling and are in the process of commercial construction: Painplex, Inflammaplex, Energyplex and Longevityplex.

This document containsforward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to a number of risks and uncertainties, many of which are outside Gold Rivers control. These include but are not limited to the impact of competitors products, services and pricing; product demand; market acceptance;new product development; reliance on key strategic alliances; the regulatory environment;fluctuations in operating results; and other risks which are detailed from time to time in the Companys filings with the Securities and Exchange Commission and/or OTC Markets. Gold River Productions disclaims any obligation to update or alter its forward-looking statements, whether as a result of new information, subsequent events or otherwise.

Original post:

Gold River Productions, Inc. (GRPS) appoints Aerospace Engineer Dr. Gabe Vlad, Chief Technical Officer - GlobeNewswire

The Omicron variant has caused an avalanche of Covid-19 cases in Australia in the past months. While most people who catch the disease experience mild symptoms, many report feeling short of breath and sluggish for weeks afterward.

Its normal to feel tired after a viral infection, and everyones recovery is different, says Janet Bondarenko, a senior respiratory physiotherapist at Alfred hospital in Melbourne. But the severity of your Covid illness doesnt necessarily predict whether you will have those lingering symptoms.

The coronavirus can damage various organs, causing ongoing fatigue, says Dr Robert Newton, professor of exercise medicine at Edith Cowan University. The cardiorespiratory system cant deliver oxygen to the working muscles efficiently. So what was a light to moderate intensity activity previously feels quite vigorous now.

Sleep and rest help your immune system to fight the disease but it is critical to start moving again to avoid further weakening of your body about seven days after the major symptoms have disappeared, Newton says.

Exercise increases capacity of muscles, heart and lungs, as well as the numbers of mitochondria the energy factories within the muscle cells which counteract the debilitating effects of the infection.

Here is a simple guide that can help you get moving again, but specialist advice from your GP or an exercise physiologist is recommended before you begin an exercise program.

There is some evidence that the practice of yoga and meditation may help improve lung health, reduce viral susceptibility and speed the recovery from acute respiratory infections thanks to their relaxing effects.

Controlling stress and anxiety is critical for recovery, says Newton. Its very important to look at strategies such as meditation, mindfulness and yoga to help the body to recover from the coronavirus infection.

In a paper published in the Journal of Alternative and Complementary Medicine, researchers stated that certain meditation, yoga asana (postures), and pranayama (breathing) practices may possibly be effective adjunctive means of [] helping to reduce severity of Covid-19 disease, including its collateral effects and sequelae.

Newton says incorporating resistance training is crucial to reactivate muscles. He says that bodyweight exercises, such as squats and push-ups on your knees, are a good starting point.

As you gradually regain your strength, you can begin to add light weights to your routine, using milk cartons or a weighted backpack.

Light resistance training triggers the production of hormones and cell-signalling molecules such as cytokines that work with the immune system to help the body repair.

According to Bondarenko, the most accessible physical activity to do after a Covid-19 infection is walking. Especially if you can do it outdoors, Newton agrees.

Anyone can easily control the intensity of their walking, they say.

Beginning with easy, short strolls is ideal, says Bondarenko. Gradually, you can increase the length and the pace of your walks as long as that does not cause you extreme fatigue or leave you feeling breathless.

Pushing through when you are still feeling sluggish after Covid-19 will not speed your recovery, says Bondarenko. It pushes you back a few steps rather than helping.

She says it is essential to gradually allow yourself extra time to return to your pre-Covid shape. Everyones recovery is different, but over time, everyone gets back to where they want to be.

Use your body as a barometer, says Newton. Test your perceived exertion to make sure you dont push the system into overtraining, because that will compromise your recovery.

Follow this link:

How to move: exercising after having Covid-19 - The Guardian

People with HIV living in the 12 states that have not adopted the Medicaid expansion face limited access to health coverage. In 2018, across sampled states, 20% of people with HIV living in non-expansion states were uninsured compared to 6% in expansion states, and those in expansion states were more likely to have Medicaid coverage (46% v 30%). Moreover, some adults with incomes below 100% of the federal poverty level (FPL) in non-expansion states fall into the coverage gap, where they do not qualify for Medicaid through an existing pathway and are not eligible for marketplace subsidies.

One provision in the Build Back Better Act (BBBA), as passed by the House of Representatives, aims to temporarily close the coverage gap, although its prospects are uncertain as negotiations continue in the Senate. It would temporarily create new coverage opportunities, including by providing a low-cost (with zero premiums) marketplace alternative for those with incomes below 100% FPL who are not otherwise eligible for Medicaid. The BBBA includes a provision to encourage states that have already expanded to maintain that status. In addition, the BBBA would also enhance cost-sharing subsidies provided under the American Rescue Plan Act (ARPA) to those with incomes between 100-138% FPL.

In this analysis, we explore the implications of the BBBAs current coverage provisions for people with HIV in select non-expansion states. We estimate the size of the population that could gain eligibility as well as their socio-demographic characteristics and examine their affordability barriers, compared to people with HIV overall. We also discuss the implications of such policy changes for the Ryan White HIV/AIDS Program, the nations HIV safety-net program. To do so, we used data from the Centers for Disease Controls and Preventions (CDC) Medical Monitoring Project (MMP), a surveillance system which produces national and state-level representative estimates of behavioral and clinical characteristics of adults with diagnosed HIV in the United States. The MMP sample includes five of the twelve non-expansion states Florida, Georgia, Mississippi, North Carolina, and Texas which together account for about 84% of people living with diagnosed HIV in non-expansion states.

We defined the group who could benefit from key BBBA coverage provisions as non-elderly adults with HIV with incomes below 139% FPL who were either uninsured or had health coverage other than from Medicaid or Medicare. Notably, this is the same population that could gain eligibility for coverage if their states expanded their Medicaid programs. (See Methodology for detail.)

Overall, we find that an estimated 55,132 (or 23%) of non-elderly individuals with HIV in sampled non-expansion states could gain eligibility for new or enhanced subsidies under the BBBA. This is also the population that could gain Medicaid eligibility, if these states expanded their programs. The share ranges by state, from an estimated 18% in both North Carolina and Georgia to 28% in Texas. (See Table 1.)

How this 23% could be impacted by BBBA is as follows. As noted, the BBBA would provide those with incomes below 100% FPL, including uninsured people in the coverage gap, with marketplace subsidies and cost-sharing assistance, making private insurance premiums free and cost-sharing minimal. We estimate that approximately 47,078 (or 16%) of non-elderly adults with HIV in the sampled non-expansion states would become eligible for this provision. BBBA would also enhance subsidies for those 100-138% FPL and we estimate beyond this 16%, an additional 7% of non-elderly people with HIV in non-expansion states would be eligible for these enhanced subsidies. Notably, BBBA provisions are temporary, and set to expire in 2025 unless renewed. Under a scenario where all sampled states expanded their Medicaid program, the full 23% of non-elderly people with HIV could gain Medicaid eligibility.

Non-elderly people with HIV in these states who could gain new coverage eligibility, including enhanced subsidies under the BBBA or through Medicaid expansion, are more likely to be under 50 years old, people of color, and uninsured compared to non-elderly people with HIV overall (Table 2):

Of which is Marketplace

32%

18%

Potentially eligible people with HIV in sampled non-expansion states are more likely to face certain affordability barriers compared to people with HIV overall. Approximately one in three (31%) of those in this potentially eligible group report being unable to pay health care bills during the past 12 months and 30% say they currently have unpaid medical bills. By comparison, 20% of non-elderly adults with HIV overall report being unable to pay health care bills during the past 12 months and 23% report they currently have unpaid medical bills. Smaller but comparable shares of those potentially eligible and people with HIV overall say they have taken the following measures to save money on medication: Skipped doses (8% v 6%), took less medicine than prescribed (7% v 6%), delayed filling a prescription (11% v 8%), asked a doctor for lower cost medication (10% for both), or used alternative therapies (6% v 4%). (Table 3.)

The Ryan White HIV/AIDS Program plays a key role in the lives of about half of all people with HIV in the U.S., and an especially important role in providing HIV care and treatment for those in non-expansion states in the coverage gap. We find that seventy percent (70%) of those who could gain new coverage opportunities under BBB or Medicaid expansion currently receive support from Ryan White, compared to 46% of non-elderly people with HIV overall, with Ryan White supporting a range of outpatient HIV services including medications although it cannot pay for non-HIV care. As such, if this group gains coverage, it could mean that state programs could shift limited Ryan White resources to expand support services that were not possible to finance in the past. In fact, people with HIV with all insurance coverage types and Ryan White experience higher rates of sustained viral suppression (an indicator for health and preventing transmission) than those with only insurance coverage and no support from the program, in large part due to these supportive, wrap around services.

We estimate that if the BBBA, as passed by the House, was enacted almost a quarter (23%) of non-elderly people with HIV in select non-expansion states could become eligible for these new coverage opportunities. This is the same share estimated to become eligible through Medicaid expansion which could be a potentially more stable coverage pathway given the currently time limited nature of the BBBA. Given high rates of uninsurance among people with HIV in non-expansion states and the prevalence of problems with medical bills, coverage gains could improve health access and affordability. And since people with HIV in non-expansion states are disproportionally people of color, new coverage opportunities could also help to address health disparities at the intersection of HIV and race/ethnicity. Coverage expansions through either pathway (the BBBA or Medicaid expansion) may also relieve the Ryan White Program from financing HIV care and treatment, allowing it to provide more robust support services, which could lead to improved care outcomes for people with HIV. In addition, a shift to coverage could mean that those previously in without affordable insurance could access care for non-HIV care needs that in the past would have not been addressed through the Ryan White Program.

Acknowledgments

The authors wish to thank Dr. Sharoda Dasgupta, Dr. Linda Beer, Tamara Carree, and Stacy Crim of the Centers for Disease Control and Prevention (CDC), who were instrumental in this work in providing access to data, guidance, and conducting statistical analysis.

This work was supported in part by the Elton John AIDS Foundation. We value our funders. KFF maintains full editorial control over all of its policy analysis, polling, and journalism activities.

Data on people with HIV are based on 2018 and 2019 data cycles from the Medical Monitoring Project (MMP), a Centers for Disease Control and Prevention (CDC) surveillance system which produces national and state-level representative estimates of behavioral and clinical characteristics of adults with diagnosed HIV in the United States.

MMP employs a two-stage, complex sampling design. First, jurisdictions are selected from all U.S. states, the District of Columbia, and Puerto Rico using a probability proportional to size sampling strategy based on AIDS prevalence at the end of 2002, such that areas with higher prevalence had a higher probability of selection. Next, adults (aged 18 years and older) with diagnosed HIV were sampled from selected jurisdictions from the National HIV Surveillance System (NHSS), a census of US persons with diagnosed HIV. During 2018 and 2019, data come from: California (including the separately funded jurisdictions of Los Angeles County and San Francisco), Delaware, Florida, Georgia, Illinois (including the separately funded jurisdiction of Chicago), Indiana, Michigan, Mississippi, New Jersey, New York (including the separately funded jurisdiction of New York City), North Carolina, Oregon, Pennsylvania (including the separately funded jurisdiction of Philadelphia), Puerto Rico, Texas (including the separately funded jurisdiction of Houston), Virginia, and Washington.

Data used in this analysis were collected via telephone or face-to-face interviews and medical record abstractions during the following periods:

For all non-elderly respondents in MMP, we examined self-reported insurance coverage. Response options included insurance programs (Medicaid, Medicare, private insurance employer and marketplace -, Ryan White HIV/AIDS Program Ryan White or the AIDS Drug Assistance Program-, Veterans Administration, Tricare or CHAMPUS coverage, other public insurance, and other unspecified insurance). Other specify responses were recoded to reflect the most accurate coverage type when possible.

We estimated weighted percentages of individuals with the following types of health care coverage: no coverage (uninsured), private insurance (with breakouts for employer coverage and marketplace coverage), Medicaid, Medicare, and other. Because respondents in MMP may indicate more than one type of coverage, we relied on a hierarchy to group people into mutually exclusive coverage categories. After removing people with any Medicaid or Medicare coverage, we categorized people into coverage according to the following hierarchy:

In most cases, this hierarchy classified individuals according to the coverage source that served as their primary payer. People who did not report any of the sources of insurance coverage were classified as uninsured.

Medicaid expansion status was identified based on KFF data. While Virginia was a non-expansion state during half of the 2018 cycle, it expanded its program and coverage became effective January 2019. Virginia was coded here as an expansion state given the forward-looking nature of this analysis.

People with HIV in non-expansion states were identified as potentially eligible for BBB assistance or Medicaid based on their state of residence, if they were under the age of 65, had incomes between 0-138% FPL, and had insurance other than Medicare or Medicaid or were uninsured. Build Back Better eligibility was also assessed to capture the estimated number and share in the coverage using the same criteria but with the poverty threshold being 0-99% FPL.

Although MMP is based on a probability sample that allows for reporting of nationally representative estimates of characteristics among people with HIV, people were not sampled with respect to Medicaid expansion status of their state of residence. Therefore, the Medicaid expansion and non-expansion coverage data presented here are representative only of the subset of states sampled that fell into each group. Insurance coverage data is self-reported by respondents and not verified. Receipt of Ryan White support is also self-reported. By relying on a hierarchy to group individuals into coverage categories, it is possible individuals were grouped into a coverage category that was not their dominant payer over the course of a year. We were unable to identify immigrants who would be ineligible for Medicaid based on immigration status but previous work suggests this percentage is likely small and would not have substantially impacted estimates. In addition, some people who are currently uninsured may already be eligible for Medicaid or other coverage.However, we expect that share to be low for several reasons. First, even prior to Medicaid expansion opportunities becoming available, the disability pathway was the most common way people with HIV became eligible for Medicaid coverage. All five states sampled use autoenrollment for people with SSI therefore limiting those eligible but not enrolled in the program. Second, Ryan White acts of payer of last resort and grantees are required to regularly assess clients for eligibility for health coverage. Given that 82% of uninsured people receive Ryan White support and the majority of the potentially eligible group identified here are uninsured, the program would likely have already identified potential coverage opportunities and assisted with enrollment, including through Medicaid, where possible. It is also important to note that respondents may not be aware of all the services they receive that are paid for by the Ryan White HIV/AIDS Program (the program provides funding directly to service organizations in many cases) and therefore, the estimates of the number of individuals who receive Ryan White HIV/AIDS Program services is likely an underestimate.

See the original post:

People With HIV in Non-Medicaid Expansion States: Who Could Gain Coverage Eligibility Through Build Back Better or Future Expansion? - Kaiser Family...

BRIDGEWATER, N.J., Feb. 17, 2022 /PRNewswire/ --Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on the Company's business and pipeline.

"Insmed made tremendous progress across our four pillars throughout 2021, and we begin 2022 from a position of strength, with seven ongoing clinical trials, commercial operations in three major territories, a pathway to ARIKAYCE growth, and a highly innovative research engine to identify what we believe to be the most promising next set of candidates," commentedWill Lewis, Chair and Chief Executive Officer of Insmed. "Importantly, our strong cash position will support advancement across our programs as we continue to lay the groundwork for what we believe will be a meaningful inflection point for the Company. I am enormously proud of our world-class team and what we have been able to achieve on behalf of patients with serious and rare diseases."

Recent Corporate Developments & Program Highlights

ARIKAYCE

Brensocatib

TPIP

Translational Medicine

Fourth Quarter and Full-Year 2021 Financial Results

Balance Sheet, Financial Guidance, and Planned Investments

As of December 31, 2021,Insmedhad cash and cash equivalents and marketable securities of$766.8 million. The Company's total operating expenses for the fourth quarter of 2021 were $155.2 million and for the full year 2021 were $563.6 million.

Insmed expects full-year 2022 revenues for ARIKAYCE to increase at least 30% year over year from 2021. The Company anticipates that its cash on hand will support its ongoing programs into 2024.

The Company plans to invest in the following key activities in 2022:

(i)

commercialization and expansion of ARIKAYCE globally;

(ii)

launch activities for ARIKAYCE in initial European countries and in Japan; and

(iii)

clinical trial activities, including (a) advancement of the frontline clinical trial program for ARIKAYCE (ARISE and ENCORE), (b) advancement of brensocatib, including the Phase 3 ASPEN study in patients with bronchiectasis, (c) advancement of the Phase 2 clinical development programs of TPIP, and (d) advancement of our translational medicine efforts.

Conference Call

Insmedwill host a conference call beginning today at8:00 AM Eastern Time. Shareholders and other interested parties may participate in the conference call by dialing (844) 200-6205 (U.S. toll free), (646) 904-5544 (U.S. local), or +1-929-526-1599 (international) and referencing access code 359415. The call will also be webcast live on the company's website atwww.insmed.com.

A replay of the conference call will be accessible approximately 1 hour after its completion throughMarch 17, 2022, by dialing (866) 813-9403 (U.S. toll free), (929) 458-6194 (U.S. local), or +44-204-525-0658 (international) and referencing access code 838814. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website atwww.insmed.com.

About ARIKAYCE

ARIKAYCE is approved inthe United Statesas ARIKAYCE(amikacin liposome inhalation suspension), in Europe as ARIKAYCELiposomal 590 mg Nebuliser Dispersion, and in Japan as ARIKAYCE inhalation 590 mg (amikacin sulfate inhalation drug product).Current international treatment guidelines recommend the use of ARIKAYCE for appropriate patients. ARIKAYCE is a novel, inhaled, once-daily formulation of amikacin, an established antibiotic that was historically administered intravenously and associated with severe toxicity to hearing, balance, and kidney function. Insmed's proprietary PULMOVANCE liposomal technology enables the delivery of amikacin directly to the lungs, where liposomal amikacin is taken up by lung macrophages where the infection resides, while limiting systemic exposure. ARIKAYCE is administered once daily using the LamiraNebulizer System manufactured by PARI Pharma GmbH (PARI).

About PARI Pharma and the LamiraNebulizer System

ARIKAYCE is delivered by a novel inhalation device, the LamiraNebulizer System, developed by PARI. Lamirais a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a vibrating, perforated membrane. Based on PARI's 100-year history working with aerosols, PARI is dedicated to advancing inhalation therapies by developing innovative delivery platforms to improve patient care.

About Brensocatib

Brensocatib is a small molecule, oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP1) being developed by Insmed for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases. DPP1 is an enzyme responsible for activating neutrophil serine proteases (NSPs), such as neutrophil elastase, in neutrophils when they are formed in the bone marrow. Neutrophils are the most common type of white blood cell and play an essential role in pathogen destruction and inflammatory mediation. In chronic inflammatory lung diseases, neutrophils accumulate in the airways and result in excessive active NSPs that cause lung destruction and inflammation. Brensocatib may decrease the damaging effects of inflammatory diseases such as bronchiectasis by inhibiting DPP1 and its activation of NSPs. Brensocatib is an investigational drug product that has not been approved for any indication in any jurisdiction.

About TPIP

Treprostinil palmitil inhalation powder (TPIP) is a dry powder formulation of treprostinil palmitil, a treprostinil prodrug consisting of treprostinil linked by an ester bond to a 16-carbon chain. Developed entirely in Insmed's laboratories, TPIP is a potentially highly differentiated prostanoid being evaluated for the treatment of patients with PAH, PH-ILD, and other rare and serious pulmonary disorders. TPIP is administered in a capsule-based inhalation device. TPIP is an investigational drug product that has not been approved for any indication in any jurisdiction.

IMPORTANT SAFETY INFORMATION FOR ARIKAYCE IN THE U.S.

WARNING: RISK OF INCREASED RESPIRATORY ADVERSE REACTIONS

ARIKAYCE has been associated with an increased risk of respiratory adverse reactions, including hypersensitivity pneumonitis, hemoptysis, bronchospasm, and exacerbation of underlying pulmonary disease that have led to hospitalizations in some cases.

Hypersensitivity Pneumonitis has been reported with the use of ARIKAYCE in the clinical trials. Hypersensitivity pneumonitis (reported as allergic alveolitis, pneumonitis, interstitial lung disease, allergic reaction to ARIKAYCE) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (3.1%) compared to patients treated with a background regimen alone (0%). Most patients with hypersensitivity pneumonitis discontinued treatment with ARIKAYCE and received treatment with corticosteroids. If hypersensitivity pneumonitis occurs, discontinue ARIKAYCE and manage patients as medically appropriate.

Hemoptysis has been reported with the use of ARIKAYCE in the clinical trials. Hemoptysis was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (17.9%) compared to patients treated with a background regimen alone (12.5%). Ifhemoptysis occurs, manage patients as medically appropriate.

Bronchospasmhas been reported with the use of ARIKAYCE in the clinical trials. Bronchospasm (reported as asthma, bronchial hyperreactivity, bronchospasm, dyspnea, dyspnea exertional, prolonged expiration, throat tightness, wheezing) was reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (28.7%)compared to patients treated with a background regimen alone (10.7%). If bronchospasm occurs during the use of ARIKAYCE, treat patients as medically appropriate.

Exacerbations of underlying pulmonary diseasehas been reported with the use of ARIKAYCE in the clinical trials. Exacerbations of underlying pulmonary disease (reported as chronic obstructive pulmonary disease (COPD), infective exacerbation of COPD, infective exacerbation of bronchiectasis) have been reported at a higher frequency in patients treated with ARIKAYCE plus background regimen (14.8%) compared to patients treated with background regimen alone (9.8%). If exacerbations of underlying pulmonary disease occur during the use of ARIKAYCE, treat patients as medically appropriate.

Anaphylaxis and Hypersensitivity Reactions:Serious and potentially life-threatening hypersensitivity reactions, including anaphylaxis, have been reported in patients taking ARIKAYCE. Signs and symptoms include acute onset of skin and mucosal tissue hypersensitivity reactions (hives, itching, flushing, swollen lips/tongue/uvula), respiratory difficulty (shortness of breath, wheezing, stridor, cough), gastrointestinal symptoms (nausea, vomiting, diarrhea, crampy abdominal pain), and cardiovascular signs and symptoms of anaphylaxis (tachycardia, low blood pressure, syncope, incontinence, dizziness). Before therapy with ARIKAYCE is instituted, evaluate for previous hypersensitivity reactions to aminoglycosides. If anaphylaxis or a hypersensitivity reaction occurs, discontinue ARIKAYCE and institute appropriate supportive measures.

Ototoxicity has been reported with the use of ARIKAYCE in the clinical trials. Ototoxicity (including deafness, dizziness, presyncope, tinnitus, and vertigo) were reported with a higher frequency in patients treated with ARIKAYCE plus background regimen (17%) compared to patients treated with background regimenalone (9.8%). This was primarily driven by tinnitus (7.6% in ARIKAYCE plus background regimen vs 0.9% in the background regimen alone arm) and dizziness (6.3% in ARIKAYCE plus background regimen vs 2.7% in the background regimen alone arm).Closely monitor patients with known or suspected auditory or vestibular dysfunction during treatment with ARIKAYCE. If ototoxicity occurs, manage patients as medically appropriate, including potentially discontinuing ARIKAYCE.

Nephrotoxicitywas observed during the clinical trials of ARIKAYCE in patients with MAC lung disease but not at a higher frequency than background regimen alone. Nephrotoxicity has been associated with the aminoglycosides. Close monitoring of patients with known or suspected renal dysfunction may be needed when prescribing ARIKAYCE.

Neuromuscular Blockade: Patients with neuromuscular disorders were not enrolled in ARIKAYCE clinical trials. Patients with known or suspected neuromuscular disorders, such as myasthenia gravis, should be closely monitored since aminoglycosides may aggravate muscle weakness by blocking the release of acetylcholine at neuromuscular junctions.

Embryo-Fetal Toxicity:Aminoglycosides can cause fetal harm when administered to a pregnant woman. Aminoglycosides, including ARIKAYCE, may be associated with total, irreversible, bilateral congenital deafness in pediatric patients exposed in utero. Patients who use ARIKAYCE during pregnancy, or become pregnant while taking ARIKAYCE should be apprised of the potential hazard to the fetus.

Contraindications: ARIKAYCE is contraindicated in patients with known hypersensitivity to any aminoglycoside.

Most Common Adverse Reactions: The most common adverse reactions in Trial 1 at an incidence 5% for patients using ARIKAYCE plus background regimen compared to patients treated with background regimen alone were dysphonia (47% vs 1%), cough (39% vs 17%), bronchospasm (29% vs 11%), hemoptysis (18% vs 13%), ototoxicity (17% vs 10%), upper airway irritation (17% vs 2%), musculoskeletal pain (17% vs 8%), fatigue and asthenia (16% vs 10%), exacerbation of underlying pulmonary disease (15% vs 10%), diarrhea (13% vs 5%), nausea (12% vs 4%), pneumonia (10% vs 8%), headache (10% vs 5%), pyrexia (7% vs 5%), vomiting (7% vs 4%), rash (6% vs 2%), decreased weight (6% vs 1%), change in sputum (5% vs 1%), and chest discomfort (5% vs 3%).

Drug Interactions:Avoid concomitant use of ARIKAYCE with medications associated with neurotoxicity, nephrotoxicity, and ototoxicity. Some diuretics can enhance aminoglycoside toxicity by altering aminoglycoside concentrations in serum and tissue. Avoid concomitant use of ARIKAYCE with ethacrynic acid, furosemide, urea, or intravenous mannitol.

Overdosage: Adverse reactions specifically associated with overdose of ARIKAYCE have not been identified.Acute toxicity should be treated with immediate withdrawal of ARIKAYCE, and baseline tests of renal function should be undertaken. Hemodialysis may be helpful in removing amikacin from the body. In all cases of suspected overdosage, physicians should contact the Regional Poison Control Center for information about effective treatment.

U.S. INDICATION

LIMITED POPULATION: ARIKAYCEis indicated in adults, who have limited or no alternative treatment options, for the treatment of Mycobacterium aviumcomplex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options. This drug is indicated for use in a limited and specific population of patients.

This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical benefit has not yet been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

Limitation of Use: ARIKAYCE has only been studied in patients with refractory MAC lung disease defined as patients who did not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. The use of ARIKAYCE is not recommended for patients with non-refractory MAC lung disease.

Patients are encouraged to report negative side effects of prescription drugs to the FDA. Visitwww.fda.gov/medwatch, or call 1800FDA1088. You can also call the Company at 1-844-4-INSMED.

Please seeFull Prescribing Information.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a growing footprint across Europe and in Japan. For more information, visit http://www.insmed.com.

Forward-looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. "Forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995, are statements that are not historical facts and involve a number of risks and uncertainties. Words herein such as "may," "will," "should," "could," "would," "expects," "plans," "anticipates," "believes," "estimates," "projects," "predicts," "intends," "potential," "continues," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) may identify forward-looking statements.

The forward-looking statements in this press release are based upon the Company's current expectations and beliefs, and involve known and unknown risks, uncertainties and other factors, which may cause the Company's actual results, performance and achievements and the timing of certain events to differ materially from the results, performance, achievements or timing discussed, projected, anticipated or indicated in any forward-looking statements. Such risks, uncertainties and other factors include, among others, the following: failure to obtain, or delays in obtaining, regulatory approvals for ARIKAYCE outside the U.S., Europe or Japan, or for the Company's product candidates in the U.S., Europe, Japan or other markets, including regulatory approval for the Lamira Nebulizer System and the drug delivery device for TPIP in each market and for each usage; failure to successfully commercialize ARIKAYCE, the Company's only approved product, in the U.S., Europe or Japan (amikacin liposome inhalation suspension, Liposomal 590 mg Nebuliser Dispersion, and amikacin sulfate inhalation drug product, respectively), or to maintain U.S., European or Japanese approval for ARIKAYCE; business or economic disruptions due to catastrophes or other events, including natural disasters or public health crises; impact of the COVID-19 pandemic and efforts to reduce its spread on the Company's business, employees, including key personnel, patients, partners and suppliers; risk that brensocatib does not prove effective or safe for patients in ongoing and future clinical studies, including the ASPEN study; risk that TPIP does not prove to be effective or safe for patients in ongoing and future clinical studies; uncertainties in the degree of market acceptance of ARIKAYCE by physicians, patients, third-party payors and others in the healthcare community; the Company's inability to obtain full approval of ARIKAYCE from the U.S. Food and Drug Administration, including the risk that the Company will not successfully or in a timely manner complete the study to validate a PRO tool and the confirmatory post-marketing clinical trial required for full approval of ARIKAYCE; inability of the Company, PARI or the Company's other third-party manufacturers to comply with regulatory requirements related to ARIKAYCE or the Lamira Nebulizer System; the Company's inability to obtain adequate reimbursement from government or third-party payors for ARIKAYCE or acceptable prices for ARIKAYCE; development of unexpected safety or efficacy concerns related to ARIKAYCE or the Company's product candidates; inaccuracies in the Company's estimates of the size of the potential markets for ARIKAYCE, brensocatib, TPIP or the Company's other product candidates or in data the Company has used to identify physicians, expected rates of patient uptake, duration of expected treatment, or expected patient adherence or discontinuation rates; the Company's inability to create an effective direct sales and marketing infrastructure or to partner with third parties that offer such an infrastructure for distribution of ARIKAYCE or any of the Company's product candidates that are approved in the future; failure to obtain regulatory approval to expand ARIKAYCE's indication to a broader patient population; risk that the Company's competitors may obtain orphan drug exclusivity for a product that is essentially the same as a product the Company is developing for a particular indication; failure to successfully predict the time and cost of development, regulatory approval and commercialization for novel gene therapy products; failure to successfully conduct future clinical trials for ARIKAYCE, brensocatib, TPIP and the Company's other product candidates due to the Company's limited experience in conducting preclinical development activities and clinical trials necessary for regulatory approval and its potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory approval, among other things; risks that the Company's clinical studies will be delayed or that serious side effects will be identified during drug development; failure of third parties on which the Company is dependent to manufacture sufficient quantities of ARIKAYCE or the Company's product candidates for commercial or clinical needs, to conduct the Company's clinical trials, or to comply with the Company's agreements or laws and regulations that impact the Company's business or agreements with the Company; failure to comply with the Company's obligations in the Company's third party agreements; the Company's inability to attract and retain key personnel or to effectively manage the Company's growth; the Company's inability to successfully integrate its recent acquisitions and appropriately manage the amount of management's time and attention devoted to integration activities; risks that the Company's acquired technologies, products and product candidates are not commercially successful; the Company's inability to adapt to its highly competitive and changing environment; risk that the Company is unable to maintain its significant customers; risk that government healthcare reform materially increases the Company's costs and damages its financial condition; the Company's inability to adequately protect its intellectual property rights or prevent disclosure of its trade secrets and other proprietary information and costs associated with litigation or other proceedings related to such matters; restrictions or other obligations imposed on the Company by agreements related to ARIKAYCE or the Company's product candidates, including its license agreements with PARI and AstraZeneca AB, and failure of the Company to comply with its obligations under such agreements; the cost and potential reputational damage resulting from litigation to which the Company is or may become a party, including product liability claims; risk that the Company's operations are subject to a material disruption in the event of a cybersecurity attack or issue; business disruptions or expenses related to the upgrade to the Company's enterprise resource planning (ERP) system; the Company's limited experience operating internationally; changes in laws and regulations applicable to the Company's business, including any pricing reform, and failure to comply with such laws and regulations; the Company's history of operating losses, and the possibility that the Company may never achieve or maintain profitability; goodwill impairment charges affecting the Company's results of operations and financial condition; inability to repay the Company's existing indebtedness and uncertainties with respect to the Company's ability to access future capital; and delays in the execution of plans to build out an additional third-party manufacturing facility approved by the appropriate regulatory authorities and unexpected expenses associated with those plans.

The Company may not actually achieve the results, plans, intentions or expectations indicated by the Company's forward-looking statements because, by their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. For additional information about the risks and uncertainties that may affect the Company's business, please see the factors discussed in Item 1A, "Risk Factors," in the Company's Annual Report on Form 10-K for the year endedDecember 31, 2021 and any subsequent Company filings with the Securities and Exchange Commission (SEC).

The Company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the SEC, to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Financial Statements Follow

INSMED INCORPORATED

Consolidated Statements of Net Loss

(in thousands, except per share data)

(unaudited)

Three Months EndedDecember 31,

Twelve Months EndedDecember 31,

2021

2020

2021

2020

Product revenues, net

$ 56,124

$ 41,415

$ 188,461

$ 164,413

Operating expenses:

Cost of product revenues (excluding amortization of intangibleassets)

13,288

10,862

44,152

39,872

Research and development

76,352

67,814

272,744

181,157

Selling, general and administrative

65,266

56,019

234,273

203,613

Amortization of intangible assets

1,262

1,258

5,052

5,003

Change in fair value of deferred and contingent considerationliabilities

(966)

-

Originally posted here:

Insmed Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business and Pipeline Update - BioSpace

Acupuncture, Medicare.gov; Bath C, How Interested Are Patients in Integrative Therapies, and How Much Are They Willing to Pay for Them, The ASCO Post, April 25, 2021; Biofeedback Therapy, CMS.gov; Calcagni N, et al., A systematic review of complementary and alternative medicine in oncology, PloS one, October 17, 2019; Cancer Patient Experience Survey Resources, December 10, 2019; Cancer Support Services Volumes, Staffing, and Operations Benchmark Generator, July 21, 2017; Cavallo J, "Integrative Medicine Showing Benefits in Cancer Management," The ASCO Post, November 15, 2012; Chiropractic services, Medicare.gov; "CMS' chemotherapy measure: What cancer programs need to know," December 3, 2019; Complementary, Alternative, or Integrative Health: What's In a Name? NCCIH.nih.gov, April 2021; "Complementary and Alternative Medicine," Cancer.gov; Garcia M, et al., Systematic review of acupuncture in cancer care: a synthesis of the evidence, Journal of Clinical Oncology, March 1, 2013; Horneber M, et al., How many cancer patients use complementary and alternative medicine: a systematic review and metaanalysis," Integrative Cancer Therapies, October 2011; "How to Keep Your Cancer Patients Out of the ED," January 2, 2018; "Integrative Medicine," Cancer.net; Integrative medicine cancer care, Aurora Health Care; Mao J, et al., Complementary and alternative medicine use among cancer survivors, Journal of Cancer Survivorship, October 6, 2010; Nahin RL, et al., Insurance Coverage for Complementary Health Approaches Among Adult Users: United States, 2002 and 2012, National Center for Health Statistics, January 2016; Nutrition therapy services, Medicare.gov; Oberoi S, et al., Association of Mindfulness-Based Interventions With Anxiety Severity in Adults With Cancer, JAMA Network Open, August 7, 2020; Sabin G, The Role of Philanthropy In The Evolution Of Integrative Medicine, Fonconsulting; Sun C, "Lesser known health perks your plan may offer," Aetna; Support services insights: Are you providing the right complementary medicine services? August 29, 2016; The support services cancer programs are providingand how theyre funding them, July 12, 2018; Wayne P, et al., Tai Chi and Qigong for cancer-related symptoms and quality of life: a systematic review and meta-analysis, Journal of Cancer Survivorship, April 12, 2018; "Will My Insurance Cover Complementary and Integrative Therapies?" American Cancer Society, August 25, 2021.

Here is the original post:

Integrative Medicine in Oncology - The Daily Briefing

Prince Charles, proud to be the Enemy of the Enlightenment.

Edzard Ernst has a new book out: Charles, The Alternative Prince: An Unauthorized Biography. I wrote a full book review that will appear in the next issue of Skeptical Inquirer magazine, but I wanted to give my readers on Science-Based Medicine a heads-up. Charles efforts to promote alternative medicine have been mentioned many times on SBM, but readers may not appreciate the depth of his folly. I know I didnt, until I read this book. The full story has never been told until now.

Ernst uses Prince Charles own words to demonstrate his ignorance of science and medicine. He thinks conventional medicine is nothing but pills and procedures. At the age of 34, he had the chutzpah to lecture to the members of the British Medical Association on the power of spiritualism, urging them to follow their intuition rather than look for scientific evidence. He has always been intuitively averse to scientific materialism and was drawn to mysticism. He fell under the influence of disreputable advisers such as Laurens van der Post, who was a compulsive liar and who impregnated a 14-year-old girl.

In addition to haranguing doctors, he has been lobbying politicians to get the NHS to pay for alternative medicine. Fortunately, his efforts have had little effect.

He says the evidence of experience is just as important as scientific evidence. He repeatedly falls for the post hoc ergo propter hoc fallacy and other logical fallacies. Ernst wonders if he is really that ignorant about science and logic, or if is this motivated ignorance, ignoring anything that disagrees with his opinions.

Prince Charles is convinced that acupuncture and Gerson therapy are fully supported by scientific evidence, and he endorses diagnostic methods like foot reflexology, iridology, and pulse diagnosis, methods that have been tested and shown not to work. He is a firm believer in homeopathy.

Perhaps the worst thing is that he is proud of being called the enemy of the Enlightenment. He is clearly anti-science. He calls for more research into alternative medicine, but he doesnt mean what we mean by research. He doesnt want research to ask if a treatment is effective, he wants it to demonstrate that it is effective, and that it would save money (which it would not).

Ernsts book offers many more fascinating details. I hope some of you will read it. You may be as shocked as I was.

Harriet Hall, MD also known as The SkepDoc, is a retired family physician who writes about pseudoscience and questionable medical practices. She received her BA and MD from the University of Washington, did her internship in the Air Force (the second female ever to do so), and was the first female graduate of the Air Force family practice residency at Eglin Air Force Base. During a long career as an Air Force physician, she held various positions from flight surgeon to DBMS (Director of Base Medical Services) and did everything from delivering babies to taking the controls of a B-52. She retired with the rank of Colonel. In 2008 she published her memoirs, Women Aren't Supposed to Fly.

View all posts

Follow this link:

Prince Charles and Alternative Medicine - Science Based Medicine

Alternative and Complementary Medicine Market 2022

Alternative and Complementary Medicine Marketreport delivers a complete overview of key components like drivers, limitations, historic and current trends, technical development, and future growth. Research report contains company analysis, size, share, revenue and sales of the company, current advancements. Alternative and Complementary Medicine market analysis also focuses on the global key top industry players in the market, with details such as company profiles, capacity, production, price, cost, revenue.

The global Alternative and Complementary Medicine market size is projected to reach USD 12180 million by 2028, from USD 5752.2 million in 2021, at a CAGR of 10.8% during 2022-2028.

Get a Sample Copy of the Report at https://www.reportsandmarkets.com/sample-request/global-alternative-and-complementary-medicine-market-4270682?utm_source=thetalkingdemocrat&utm_medium=47

The top players are concentrating mostly on technical developments in order to increase efficiency. The long-term growth patterns for this market can be taken by continuing the current development progresses and financial strength to participate in the best strategies.

By Company @ Iyengar Yoga Institute, Nordic Naturals, Herbal Hills, John Schumachers Unity Woods Yoga Center, Pure encapsulations, Yoga Tree, Columbia Nutritional Inc., Helio USA Inc., Deepure Plus, Quantum Touch Inc, The Healing Company, and Herb Pharm

By Region

TOC of Global Alternative and Complementary Medicine Market Insights and Forecast to 2028

1 Report Business Overview

1.1 Study Scope

1.2 Market Analysis by Type

1.2.1 Global Alternative and Complementary Medicine Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

1.3 Market by Application

1.3.1 Global Alternative and Complementary Medicine Market Size Growth Rate by Application, 2017 VS 2021 VS 2028

1.4 Study Objectives

1.5 Years Considered

2 Global Growth Trends

2.1 Global Alternative and Complementary Medicine Market Perspective (2017-2028)

2.2 Alternative and Complementary Medicine Growth Trends by Region

2.2.1 Alternative and Complementary Medicine Market Size by Region: 2017 VS 2021 VS 2028

2.2.2 Alternative and Complementary Medicine Historic Market Size by Region (2017-2022)

2.2.3 Alternative and Complementary Medicine Forecasted Market Size by Region (2023-2028)

2.3 Alternative and Complementary Medicine Market Dynamics

2.3.1 Alternative and Complementary Medicine Industry Trends

2.3.2 Alternative and Complementary Medicine Market Drivers

2.3.3 Alternative and Complementary Medicine Market Challenges

2.3.4 Alternative and Complementary Medicine Market Restraints

Inquire or Share Your Questions If Any Before the Purchasing This Report:https://www.reportsandmarkets.com/enquiry/global-alternative-and-complementary-medicine-market-4270682?utm_source=thetalkingdemocrat&utm_medium=47

3 Competition Landscape by Key Players

3.1 Global Top Alternative and Complementary Medicine Players by Revenue

3.1.1 Global Top Alternative and Complementary Medicine Players by Revenue (2017-2022)

3.1.2 Global Alternative and Complementary Medicine Revenue Market Share by Players (2017-2022)

3.2 Global Alternative and Complementary Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.3 Players Covered: Ranking by Alternative and Complementary Medicine Revenue

3.4 Global Alternative and Complementary Medicine Market Concentration Ratio

3.4.1 Global Alternative and Complementary Medicine Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Alternative and Complementary Medicine Revenue in 2021

3.5 Alternative and Complementary Medicine Key Players Head office and Area Served

3.6 Key Players Alternative and Complementary Medicine Product Solution and Service

3.7 Date of Enter into Alternative and Complementary Medicine Market

3.8 Mergers & Acquisitions, Expansion Plans

4 Alternative and Complementary Medicine Breakdown Data by Type

4.1 Global Alternative and Complementary Medicine Historic Market Size by Type (2017-2022)

4.2 Global Alternative and Complementary Medicine Forecasted Market Size by Type (2023-2028)

5 Alternative and Complementary Medicine Breakdown Data by Application

5.1 Global Alternative and Complementary Medicine Historic Market Size by Application (2017-2022)

5.2 Global Alternative and Complementary Medicine Forecasted Market Size by Application (2023-2028)

Table of contents:

Alternative and Complementary Medicine Global Market Research Report 2021 (Updated)

1 Market Overview

2 Manufacturers Profiles

3 Global Alternative and Complementary Medicine Sales, Revenue, Market Share and Competition by Manufacturer

4 Global Alternative and Complementary Medicine Market Analyses by Regions

5 North America Alternative and Complementary Medicine by Country

6 Europe Alternative and Complementary Medicine by Country

7 Asia-Pacific Alternative and Complementary Medicine by Country

8 South America Alternative and Complementary Medicine by Country

9 Middle East and Africa Alternative and Complementary Medicine by Countries

10 Global Alternative and Complementary Medicine Market Segment by Type

11 Global Alternative and Complementary Medicine Market Segment by Application

12 Alternative and Complementary Medicine Market Forecast (2021-2027)

13 Sales Channel, Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

About Us:

Reports and Markets is not just another company in this domain but is a part of a veteran group called Algoro Research Consultants Pvt. Ltd. It offers premium progressive statistical surveying, market research reports, analysis & forecast data for a wide range of sectors both for the government and private agencies all across the world. The database of the company is updated on a daily basis. Our database contains a variety of industry verticals that include: Food Beverage, Automotive, Chemicals and Energy, IT & Telecom, Consumer, Healthcare, and many more. Each and every report goes through the appropriate research methodology, Checked from the professionals and analysts.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Link:

Alternative and Complementary Medicine Market Insights by Business Overview, Scope, Growth Rate, Market Size and Forecast to 2028 Talking Democrat -...